Thinly traded nano cap Altimmune (NASDAQ:ALT) is up 6% premarket on robust volume in reaction to preclinical data on ALT-702.
Three doses of ALT-702, injected into one tumor
mass over five days in conjunction with an anti-CTLA4 antibody
administered intraperitoneally (into the body cavity), were evaluated in
a mouse model based on the CT26 colorectal carcinoma cell line.
Tumor regression was observed in both injected and
non-injected lesions and overall survival was “markedly better” for the
combo compared to either agent alone.
The company says ALT-702
is a targeted tumor immunostimulant, a dual TLR7/8 agonist conjugated
to its depot-forming technology, designed to reverse local
immunosuppression within the tumor microenvironment and stimulate
systemic antitumor immune responses.
https://seekingalpha.com/news/3533898-altimmune-up-6-premarket-on-encouraging-altminus-702-data
